JP2012523376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523376A5 JP2012523376A5 JP2011552217A JP2011552217A JP2012523376A5 JP 2012523376 A5 JP2012523376 A5 JP 2012523376A5 JP 2011552217 A JP2011552217 A JP 2011552217A JP 2011552217 A JP2011552217 A JP 2011552217A JP 2012523376 A5 JP2012523376 A5 JP 2012523376A5
- Authority
- JP
- Japan
- Prior art keywords
- sns
- pharmaceutical composition
- composition according
- cancer
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- XZAFZXJXZHRNAQ-STQMWFEESA-N vosaroxin Chemical compound C1[C@H](OC)[C@@H](NC)CN1C1=CC=C2C(=O)C(C(O)=O)=CN(C=3SC=CN=3)C2=N1 XZAFZXJXZHRNAQ-STQMWFEESA-N 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 108700020462 BRCA2 Proteins 0.000 claims 9
- 101150008921 Brca2 gene Proteins 0.000 claims 9
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 1
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 230000007035 DNA breakage Effects 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000002944 hormone and hormone analog Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229910001410 inorganic ion Inorganic materials 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000000649 purine antagonist Substances 0.000 claims 1
- 239000003790 pyrimidine antagonist Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15644909P | 2009-02-27 | 2009-02-27 | |
| US61/156,449 | 2009-02-27 | ||
| US17001309P | 2009-04-16 | 2009-04-16 | |
| US61/170,013 | 2009-04-16 | ||
| PCT/US2010/025737 WO2010099526A1 (en) | 2009-02-27 | 2010-03-01 | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060900A Division JP2015145396A (ja) | 2009-02-27 | 2015-03-24 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523376A JP2012523376A (ja) | 2012-10-04 |
| JP2012523376A5 true JP2012523376A5 (enExample) | 2013-04-18 |
| JP5936862B2 JP5936862B2 (ja) | 2016-06-22 |
Family
ID=42224275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552217A Expired - Fee Related JP5936862B2 (ja) | 2009-02-27 | 2010-03-01 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
| JP2015060900A Pending JP2015145396A (ja) | 2009-02-27 | 2015-03-24 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060900A Pending JP2015145396A (ja) | 2009-02-27 | 2015-03-24 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20120148564A1 (enExample) |
| EP (2) | EP2400959A1 (enExample) |
| JP (2) | JP5936862B2 (enExample) |
| KR (2) | KR20110132400A (enExample) |
| CN (2) | CN104688732A (enExample) |
| AU (2) | AU2010217796B2 (enExample) |
| CA (1) | CA2753261A1 (enExample) |
| IL (1) | IL214784A0 (enExample) |
| MX (1) | MX348412B (enExample) |
| NZ (1) | NZ594829A (enExample) |
| RU (1) | RU2558835C2 (enExample) |
| SG (2) | SG10201400258SA (enExample) |
| WO (1) | WO2010099526A1 (enExample) |
| ZA (1) | ZA201106199B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005222622B2 (en) | 2004-03-15 | 2011-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | SNS-595 and methods of using the same |
| AU2008317400B2 (en) | 2007-10-22 | 2014-10-02 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy |
| EP3284745A1 (en) | 2008-12-31 | 2018-02-21 | Sunesis Pharmaceuticals, Inc. | Composition of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| CN104688732A (zh) * | 2009-02-27 | 2015-06-10 | 逊尼希思制药公司 | 利用sns-595治疗具有降低的brca2活性的癌症对象的方法 |
| UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| US8470817B2 (en) | 2009-10-26 | 2013-06-25 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
| WO2023110045A1 (en) | 2021-12-15 | 2023-06-22 | Y-Mabs Therapeutics, Inc. | Scfv and antibodies with reduced multimerisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6024A (en) * | 1849-01-09 | Cast-iron gar-wheel | ||
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| ATE209645T1 (de) | 1994-06-14 | 2001-12-15 | Dainippon Pharmaceutical Co | Neue verbindung, verfahren zu ihrer herstellung und antitumormittel |
| JPH10173986A (ja) | 1996-12-16 | 1998-06-26 | Sony Corp | 移動体撮影装置 |
| CA2547077C (en) * | 2003-12-01 | 2015-11-03 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
| AU2005222622B2 (en) | 2004-03-15 | 2011-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | SNS-595 and methods of using the same |
| AU2006287149B2 (en) * | 2005-09-02 | 2013-05-23 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| MX2008015775A (es) | 2006-06-12 | 2009-04-17 | Sunesis Pharmaceuticals Inc | Compuestos y composiciones para tratamiento de cancer. |
| US7790274B2 (en) | 2006-08-02 | 2010-09-07 | High Impact Technology, Llc | Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials |
| EP2155897A2 (en) * | 2007-03-30 | 2010-02-24 | Source Precision Medicine, Inc. d/b/a Source MDX. | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| CN104688732A (zh) * | 2009-02-27 | 2015-06-10 | 逊尼希思制药公司 | 利用sns-595治疗具有降低的brca2活性的癌症对象的方法 |
-
2010
- 2010-03-01 CN CN201410799921.9A patent/CN104688732A/zh active Pending
- 2010-03-01 SG SG10201400258SA patent/SG10201400258SA/en unknown
- 2010-03-01 EP EP10707173A patent/EP2400959A1/en not_active Withdrawn
- 2010-03-01 RU RU2011139323/15A patent/RU2558835C2/ru not_active IP Right Cessation
- 2010-03-01 JP JP2011552217A patent/JP5936862B2/ja not_active Expired - Fee Related
- 2010-03-01 KR KR1020117022340A patent/KR20110132400A/ko not_active Ceased
- 2010-03-01 US US13/203,718 patent/US20120148564A1/en not_active Abandoned
- 2010-03-01 AU AU2010217796A patent/AU2010217796B2/en not_active Ceased
- 2010-03-01 MX MX2011008994A patent/MX348412B/es active IP Right Grant
- 2010-03-01 CN CN2010800172031A patent/CN102405045A/zh active Pending
- 2010-03-01 WO PCT/US2010/025737 patent/WO2010099526A1/en not_active Ceased
- 2010-03-01 CA CA2753261A patent/CA2753261A1/en not_active Abandoned
- 2010-03-01 NZ NZ594829A patent/NZ594829A/xx not_active IP Right Cessation
- 2010-03-01 SG SG2011061512A patent/SG173855A1/en unknown
- 2010-03-01 EP EP17179348.2A patent/EP3287126A1/en not_active Withdrawn
- 2010-03-01 KR KR1020177010758A patent/KR20170046193A/ko not_active Ceased
-
2011
- 2011-08-22 IL IL214784A patent/IL214784A0/en unknown
- 2011-08-23 ZA ZA2011/06199A patent/ZA201106199B/en unknown
-
2014
- 2014-09-03 US US14/476,606 patent/US20150202189A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015060900A patent/JP2015145396A/ja active Pending
- 2015-07-30 AU AU2015207901A patent/AU2015207901A1/en not_active Abandoned
-
2016
- 2016-08-10 US US15/233,860 patent/US20170182015A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Topatana et al. | Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation | |
| Wagner et al. | Senescence as a therapeutically relevant response to CDK4/6 inhibitors | |
| Hirpara et al. | Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance | |
| Huang et al. | Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia–mutated kinase–mediated DNA damage response | |
| Yan et al. | Aurora‐A kinase: a potent oncogene and target for cancer therapy | |
| Ganguly et al. | Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers | |
| Rajeshkumar et al. | MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts | |
| Wicki et al. | First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13) | |
| Gild et al. | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells | |
| JP2012523376A5 (enExample) | ||
| Patel et al. | Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition | |
| Magnussen et al. | Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma | |
| Cocco et al. | Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo | |
| Tryfonidis et al. | A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378) | |
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| Lian et al. | Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation | |
| Yang et al. | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | |
| Narayanan et al. | Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation | |
| Ma et al. | Inhibition of farnesyltransferase potentiates NOTCH-targeted therapy against glioblastoma stem cells | |
| RU2011139323A (ru) | Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2 | |
| Miyamoto et al. | Synergistic effects of olaparib and DNA-damaging agents in oesophageal squamous cell carcinoma cell lines | |
| Pan et al. | An unbiased high‐throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer | |
| US10188666B2 (en) | Dendrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors | |
| Mann et al. | Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse | |
| Lin et al. | Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer |